CV Therapeutics Receives Notices of Allowance From U.S. Patent and Trademark Office and European Patent Office for Drug-Eluting
October 05 2006 - 8:00AM
PR Newswire (US)
PALO ALTO, Calif., Oct. 5 /PRNewswire-FirstCall/ -- CV
Therapeutics, Inc. (NASDAQ:CVTX) announced today that it has
received Notices of Allowance from the U.S. Patent and Trademark
Office and from the European Patent Office for its proprietary
biopolymer stent coating technology. Preclinical study results
suggest that CV Therapeutics' proprietary biopolymer stent coating
technology could potentially improve the performance of stents
coated with drugs such as paclitaxel or rapamycin by potentially
limiting cracking and peeling following implantation of the stent.
As shown in preclinical studies, the proprietary CV Therapeutics
biopolymer stent coating does not entomb the drug and is designed
to control drug release rate more precisely and allows for the
complete release of drug, leaving a bare metal stent in place. The
inflammatory responses and biocompatibility observed with CV
Therapeutics' technology in preclinical studies are similar to
results seen with bare metal stents. Stents are small metal
tube-shaped devices that can be inserted into clogged blood vessels
to reopen them. Commercially available stents with drugs in the
coating have been shown to reduce the frequency of restenosis,
which is the reclosure of the vessel after the stent has been
implanted. About CV Therapeutics CV Therapeutics, Inc.,
headquartered in Palo Alto, California, is a biopharmaceutical
company focused on applying molecular cardiology to the discovery,
development and commercialization of novel, small molecule drugs
for the treatment of cardiovascular diseases. CV Therapeutics'
approved products include Ranexa(R) (ranolazine extended- release
tablets) and ACEON(R) (perindopril erbumine) Tablets. Ranexa is
indicated for the treatment of chronic angina in patients who have
not achieved an adequate response with other antianginal drugs, and
should be used in combination with amlodipine, beta-blockers or
nitrates. In addition, CV Therapeutics co-promotes ACEON(R), an ACE
inhibitor, for reduction of the risk of cardiovascular mortality or
nonfatal myocardial infarction in patients with stable coronary
artery disease and treatment of essential hypertension. CV
Therapeutics also has other clinical and preclinical drug
development candidates and programs, including regadenoson, which
is being developed for potential use as a pharmacologic stress
agent in myocardial perfusion imaging studies. Regadenoson has not
been approved for marketing by any regulatory authorities. Except
for the historical information contained herein, the matters set
forth in this press release are forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are subject to risks and uncertainties that may cause
actual results to differ materially, including; the conduct and
timing of studies; commercialization of products; market acceptance
of products; intellectual property protection and disputes; and
other risks detailed from time to time in CV Therapeutics' SEC
reports, including its Quarterly Report on Form 10-Q for the
quarter ended June 30, 2006. CV Therapeutics disclaims any intent
or obligation to update these forward-looking statements.
DATASOURCE: CV Therapeutics, Inc. CONTACT: John Bluth, Senior
Director, Corporate Communications & Investor Relations,
+1-650-384-8850, or Brendan Doherty, Manager, Public Relations,
+1-650-384-8372, both of CV Therapeutics, Inc. Web site:
http://www.cvt.com/
Copyright
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Sep 2023 to Sep 2024